Aosaikang Pharma Says ASKB589 Trials Shows Positive Results on Gastric Cancer Patients

MT Newswires Live2025-01-29

Beijing Aosaikang Pharmaceutical's (SHE:002755) unit, Askgene, said its study of the drug ASKB589 showed positive results in patients with gastric cancer, according to a Shenzhen Stock Exchange disclosure on Jan. 24.

The phase Ib/II clinical trials looked into the effect of the drug combined with CAPOX, or oxaliplatin and capecitabine, and PD-1 inhibitors as a treatment for advanced gastric or esophageal gastric junction adenocarcinoma.

The pharmaceutical company said that patients who took the drug combination showed sustained survival benefits and good tolerability and they did not have any additional adverse reactions. A total of 62 patients were enrolled in the trial.

The results were published and announced at the American Society of Clinical Oncology Gastrointestinal Cancer Symposium.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2507084665?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-29 12:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2507084665","market":"sg","top_or_hot":-1,"title":"Aosaikang Pharma Says ASKB589 Trials Shows Positive Results on Gastric Cancer Patients","media":"MT Newswires Live","content":"<html><body><p> Beijing Aosaikang Pharmaceutical's (SHE:002755) unit, Askgene, said its study of the drug ASKB589 showed positive results in patients with gastric cancer, according to a Shenzhen Stock Exchange disclosure on Jan. 24.</p><p>The phase Ib/II clinical trials looked into the effect of the drug combined with CAPOX, or oxaliplatin and capecitabine, and PD-1 inhibitors as a treatment for advanced gastric or esophageal gastric junction adenocarcinoma.</p><p>The pharmaceutical company said that patients who took the drug combination showed sustained survival benefits and good tolerability and they did not have any additional adverse reactions. A total of 62 patients were enrolled in the trial.</p><p>The results were published and announced at the American Society of Clinical Oncology Gastrointestinal Cancer Symposium.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Aosaikang Pharma Says ASKB589 Trials Shows Positive Results on Gastric Cancer Patients</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAosaikang Pharma Says ASKB589 Trials Shows Positive Results on Gastric Cancer Patients\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-01-29 12:33</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Beijing Aosaikang Pharmaceutical's (SHE:002755) unit, Askgene, said its study of the drug ASKB589 showed positive results in patients with gastric cancer, according to a Shenzhen Stock Exchange disclosure on Jan. 24.</p><p>The phase Ib/II clinical trials looked into the effect of the drug combined with CAPOX, or oxaliplatin and capecitabine, and PD-1 inhibitors as a treatment for advanced gastric or esophageal gastric junction adenocarcinoma.</p><p>The pharmaceutical company said that patients who took the drug combination showed sustained survival benefits and good tolerability and they did not have any additional adverse reactions. A total of 62 patients were enrolled in the trial.</p><p>The results were published and announced at the American Society of Clinical Oncology Gastrointestinal Cancer Symposium.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"002755","symbol_name":"奥赛康","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2507084665","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2507084665","pubTimestamp":1738125205,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Beijing Aosaikang Pharmaceutical's  unit, Askgene, said its study of the drug ASKB589 showed positive results in patients with gastric cancer, according to a Shenzhen Stock Exchange disclosure on Jan. 24.The phase Ib/II clinical trials looked into the effect of the drug combined with CAPOX, or oxaliplatin and capecitabine, and PD-1 inhibitors as a treatment for advanced gastric or esophageal gastric junction adenocarcinoma.The pharmaceutical company said that patients who took the drug combination showed sustained survival benefits and good tolerability and they did not have any additional adverse reactions. A total of 62 patients were enrolled in the trial.The results were published and announced at the American Society of Clinical Oncology Gastrointestinal Cancer Symposium.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"002755":"奥赛康","BK0239":"医药制造","BK0028":"国家队"},"translate_title":"奥赛康药业称ASKB589试验对胃癌患者显示积极结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"002755":0.9},"content_text":"Beijing Aosaikang Pharmaceutical's (SHE:002755) unit, Askgene, said its study of the drug ASKB589 showed positive results in patients with gastric cancer, according to a Shenzhen Stock Exchange disclosure on Jan. 24.The phase Ib/II clinical trials looked into the effect of the drug combined with CAPOX, or oxaliplatin and capecitabine, and PD-1 inhibitors as a treatment for advanced gastric or esophageal gastric junction adenocarcinoma.The pharmaceutical company said that patients who took the drug combination showed sustained survival benefits and good tolerability and they did not have any additional adverse reactions. A total of 62 patients were enrolled in the trial.The results were published and announced at the American Society of Clinical Oncology Gastrointestinal Cancer Symposium.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.1","shortVersion":"4.36.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2507084665","isCrawlerRequest":true}